Next 10 |
Placentia, California--(Newsfile Corp. - May 2, 2024) - Today, InVitro International (OTC Pink: IVRO), announced second quarter FY '24 sales of $210,615, up 5.8% compared to $199,090 for the same period FY '23. Net income in the quarter was $47,674 versus losses of $3,356 in '23. First half FY '2...
Placentia, California--(Newsfile Corp. - February 14, 2024) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technologies, announced first Quarter FY '24 sales ending December 31, 2023, of $211,625 up 1.1% vs. the...
Placentia, California--(Newsfile Corp. - November 13, 2023) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technologies, announced sales for FY '23 ending September 30, 2023 of $792,629 ( -7% vs FY '22); net inc...
2023-08-10 11:21:06 ET InVitro International press release ( OTCPK:IVRO ): Q3 Revenue of $0.2M. Net loss of $13,162 was a 58% improvement over last year's $28,938 third quarter loss. For further details see: InVitro International reports Q3 results
Placentia, California--(Newsfile Corp. - August 9, 2023) - Today, InVitro International (OTC Pink: IVRO), the 38 year pioneer developer and marketer of animal free testing methods, announced Fiscal 2023 third quarter sales of $199,855, off 16% from prior year's third quarter. However, the net l...
Placentia, California--(Newsfile Corp. - May 11, 2023) - Today InVitro International (OTC Pink: IVRO), the 38 year pioneer developer and marketer of animal free testing methods, announced Fiscal 2023 second quarter sales of $199,090, off 23% from the same quarter Fiscal 2022; YTD sales are now of...
InVitro International press release ( OTCPK:IVRO ): Q1 Operating loss of $31K Revenue of $0.21M (+14% Y/Y). For further details see: InVitro International reports Q1 results
Placentia, California--(Newsfile Corp. - February 8, 2023) - Today InVitro International (OTC Pink: IVRO), the 37 year pioneer developer and marketer of animal free testing methods, announced first fiscal quarter sales of $209,250, an increase of 14% over the same quarter last year. An operating ...
Placentia, California--(Newsfile Corp. - December 8, 2022) - InVitro International (OTC Pink: IVRO) today announced full year FY2022 sales results of $853,511 (-15%) and net income of $21,276 (-79%). CEO W. Richard Ulmer remarked: "We remain extremely enthusiastic regarding the future of NON-Ani...
Placentia, California--(Newsfile Corp. - November 16, 2022) - InVitro International (OTC Pink: IVRO) today announced it has signed its first Letter of Intent (LOI) to acquire a privately owned, U.S. based testing laboratory. Over many years this laboratory has served IVRO targeted markets prof...
News, Short Squeeze, Breakout and More Instantly...
Placentia, California--(Newsfile Corp. - May 2, 2024) - Today, InVitro International (OTC Pink: IVRO), announced second quarter FY '24 sales of $210,615, up 5.8% compared to $199,090 for the same period FY '23. Net income in the quarter was $47,674 versus losses of $3,356 in '23. First half FY '2...
Placentia, California--(Newsfile Corp. - February 14, 2024) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technologies, announced first Quarter FY '24 sales ending December 31, 2023, of $211,625 up 1.1% vs. the...
Placentia, California--(Newsfile Corp. - November 13, 2023) - Today, InVitro International (OTC Pink: IVRO), the 38-year-old pioneer developer and marketer of globally approved NON-Animal test technologies, announced sales for FY '23 ending September 30, 2023 of $792,629 ( -7% vs FY '22); net inc...